Source comparison
IGF-1 Response: Oral Secretagogue vs Injectable HGH
Both MK-677 and recombinant HGH elevate serum IGF-1, but the kinetics differ. HGH injections produce a sharp IGF-1 spike within 8–12 hours post-administration, peaking around 18–24 hours, then declining unless re-dosed. Daily HGH protocols maintain relatively
This comparison does not assign a generated winner or score.
- Both MK-677 and recombinant HGH elevate serum IGF-1, but the kinetics differ. HGH injections produce a sharp IGF-1 spike within 8–12 hours post-administration, peaking around 18–24 hours, then declining unless re-dosed. Daily HGH protocols maintain relatively stable IGF-1 levels, but at the cost of continuous exogenous input. MK-677 produces a slower, sustained IGF-1 rise. Clinical data shows plateau levels achieved within 4–6 weeks of daily 25mg dosing, after which IGF-1 remains elevated as long as dosing continues.
- A key distinction: HGH's IGF-1 elevation is dose-dependent and immediate. If you inject 2 IU today, your IGF-1 rises predictably within 24 hours. MK-677's effect is cumulative. The first dose won't spike IGF-1 dramatically, but consistent daily administration builds to a sustained plateau. The JCEM study referenced earlier found that after 12 months of MK-677 at 25mg daily, mean IGF-1 SDS (standard deviation score) increased by 1.8 units. Clinically meaningful and stable across the study duration.
- Here's what most comparisons miss: IGF-1 half-life is 12–15 hours regardless of whether it was triggered by endogenous GH (via MK-677) or exogenous GH (via injection). The difference is upstream. How the GH pulse pattern influences downstream anabolic signaling. Pulsatile GH secretion (preserved with MK-677) appears to favour certain metabolic pathways, particularly lipolysis and glucose metabolism, more effectively than sustained GH elevation. A 2018 study in Metabolism: Clinical and Experimental found that pulsatile GH administration improved insulin sensitivity markers compared to continuous-infusion GH at equivalent total dose.
- For research applications requiring stable, long-term IGF-1 elevation without daily injections, MK-677 offers a compelling pathway. Our experience shows that protocols evaluating body recomposition, recovery metrics, or bone density benefit from the consistency. No injection-site variability, no missed doses due to injection anxiety, and no need for refrigerated storage during travel. Products like the Body Recomp Bundle combine MK-677 with complementary peptides designed to support lean mass retention and metabolic flexibility.